Not affiliated with the official program of AAO 2025
Monday, October 20, 2025
6:00 AM – 6:15 AM: Breakfast/Registration
6:15 AM – 7:45 AM: Symposium
Hyatt Regency Orlando
9801 International Drive, Orlando, Florida
Meeting Room: Ballroom T
PROGRAM FEATURES
- Interactive, case-based learning environment
- Downloadable whiteboard animations
- Create your own personalized poster
PRESENTING FACULTY
 |
Peter K. Kaiser, MD Chaney Family Endowed Chair in Ophthalmology Research Cole Eye Institute Professor of Ophthalmology Case Western Reserve School of Medicine Cleveland, Ohio |
 |
Jeffrey S. Heier, MD Co-President and Medical Director Ophthalmic Consultants of Boston Assistant Professor, Ophthalmology Tufts University School of Medicine Courtesy Staff, Ophthalmology Massachusetts Eye and Ear Infirmary Boston, Massachusetts |
PROGRAM OVERVIEW
This symposium will overview the advances in the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), including considerations for the timely diagnosis and the application of complement inhibition therapies. Through expert-led presentations, animations, and case-based discussions, this activity will highlight best practices to optimize diagnosis, review the rationale for targeting the complement system in GA, as well as overview the efficacy and safety of complement inhibition therapies and how they have revolutionized treatment paradigms. In addition, this activity will provide key clinical pearls on how to apply these therapies to appropriate patients and optimize patient selection, as well as review key emerging therapies.
LEARNING OBJECTIVES
- Identify key clinical features of GA using diagnostic imaging modalities such as FAF and OCT
- Explain the role of the complement cascade in the pathogenesis of GA and its implications for targeted therapeutic development
- Apply evidence-based strategies to initiate and monitor treatment with complement inhibition therapies in patients with GA based on the latest clinical evidence
- Assess investigational therapies for GA in late-stage clinical development and their potential roles in future treatment paradigms
TARGET AUDIENCE
This activity is designed to educate ophthalmologists, optometrists, and APPs who care for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Medical Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group at [email protected]
